PHARMACEUTICAL 2016

XOMA Royalty Corp
Rank 242 of 295



PHARMACEUTICAL 2016

XOMA Royalty Corp
Rank 242 of 295

The relative strengths and weaknesses of XOMA Royalty Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of XOMA Royalty Corp compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 6.5% points.The greatest weakness of XOMA Royalty Corp is the variable Stockholders Equity, reducing the Economic Capital Ratio by 172% points.

The company's Economic Capital Ratio, given in the ranking table, is 139%, being 124% points below the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	72,219
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	23,295
Liabilities, Non-Current	43,430
Other Assets	664
Other Compr. Net Income	0
Other Expenses	-6,220
Other Liabilities	10,464
Other Net Income	5,500
Other Revenues	55,447
Property and Equipment	1,997
Research and Development	70,852
Selling, General and Administrative Expense	20,620

Output Variable	Value in 1000 USD
Assets	74,880
Liabilities	77,189
Expenses	85,252
Revenues	55,447
Stockholders Equity	-2,309
Net Income	-24,305
Comprehensive Net Income	-24,305
BaseVar	149,134
ECR before LimitedLiability	-39%
Economic Capital Ratio	139%